Very important presence of HM hospitals in the annual Congress of ASCO, with 13 accepted presentations and 37 professionals involved in them.

-Dr. Calvo, director of clinical research and the CIOCC START Madrid-CIOCC, defended one of the ten oral presentations of new drugs that were made at ASCO this year: an innovative drug that inhibits one of the fundamental ways of transmission of procancerigenas signals in tumor cells, and which was administered for the first time in the world to patients in this study and in the START Madrid-CIOCC unit

-La DRA. Laura García Estévez, responsible for the mother of the CIOCC multidisciplinary unit, presented research on innovative combinations of biological drugs and cytotoxic, trastuzumab, bevacizumab, and paclitaxel, for the preoperative treatment of breast cancer

-El Dr. Manuel Hidalgo, director of the CIOCC, is responsible for a study on the combined use of nab-paclitaxel and Gemcitabine in the treatment of pancreatic cancer SCRA; and other work on personalized Oncology medicine

Madrid, June 2012.- El Centro Integral Oncology Clara Campal (CIOCC) participated with twelve presentations in poster format and one in oral communication – from the total of 18 cancer clinical research papers – at the annual meeting of the American Society of Clinical Oncology (ASCO)(, by its acronym in English), recently held in Chicago (United States), makes it, possibly in the Spanish hospital with more relevant presence ” in the professional citation of most important Oncology of the year around the world, says Dr. Emiliano Calvo, director of clinical research of the CIOCC and the unit START Madrid-CIOCC.

Dr. Manuel Hidalgo

Desde luego, hay datos que respaldan esta afirmación: seis de dichos trabajos partieron de iniciativas de diferentes oncólogos de HM Hospitales y, de hecho, se han realizado prácticamente en su totalidad en el grupo hospitalario y hasta 37 médicos investigadores y profesionales de la plataforma multidisciplinar oncológica de HM Hospitales han sido autores de los estudios enviados. These professionals form part of the regular teams of different areas of Oncology specialization of the Group – Medical Oncology, radiation oncology, oncological surgery, radiology, Nuclear Medicine, laboratory of therapeutic targets …-, as well as their associated institutional programs – unit START Madrid-CIOCC and agreement with the Center National Foundation for cancer research (CNIO).

Dr. Calvo explains that the papers presented include different therapeutic areas from digestive, breast, Genitourinary or lung tumors the Pharmacoeconomics and the early development of new drugs in phase I studies.

Outstanding studies

Of them, the director of clinical research and the CIOCC START Madrid-CIOCC highlights one of the ten oral presentations of new drugs made at ASCO this year, and whose responsibility is the same: an innovative drug that inhibits one of the fundamental ways of transmission of procancerigenas signals tumor cells (akt/p70S6K) and that he managed for the first time in the world to patients in this study and in the START Madrid-CIOCC unit.

Dra. Laura García Estévez

in addition, the early development of innovative cancer drugs START Madrid-CIOCC Unit presented five papers on different innovative drugs in poster format.

They also stressed the research presented by Dr. Laura García Estévez, responsible for the multidisciplinary unit of breast trastuzumab and bevacizumab, paclitaxel, for the preoperative treatment of breast cancer.

Dr. Emiliano Calvo

El Dr. Calvo hace igualmente hincapié en el estudio presentado por el Dr. Manuel Hidalgo, director del CIOCC, que arrojó resultados positivos sobre el uso combinado de nab-paclitaxel y gemcitabina en el tratamiento de cáncer de páncreas extirpable; y en otros trabajos presentados por el mismo experto sobre medicina personalizada en Oncología basada en la evaluación de sensibilidad a paneles de fármacos antitumorales de ccells circulating tumorigenicas (quimiogramas) and grafts of tumours of patients in animal models (xenografts avatar), as well as in obtaining full genomic profile specific tumors from patients in order to better define the therapeutic targets to which apply the available drugs.

Be a personalized medicine that is no longer so much the future of Oncology, but gaining more prominence in the current strategies of cancer approach and that, Furthermore, according to studies presented also in this edition of ASCO, is demonstrating, as well as beneficial in medical terms, not only manageable, but also cost-effective for the health system.

World reference in Oncology Congress

Around 35,000 worldwide oncology specialists meet each year in Chicago at the World Congress of reference in Clinical Oncology, where are presented and share the most important discoveries in the fight against cancer. Each year, these advances include the latest results from cancer clinical trials and studies with new drugs that can change the practice in Oncology and are communicated to the experts and to the rest of the society in a multitude of ways to be focus of great media impact global with respect to the most relevant findings in the fight against the ACcancer.

This year sent a total of 5.264 research papers from all countries of the world, of which have been selected, its scientific interest for its presentation and comments in poster format, a total of 2.487 studies. In them, 5% more relevant in different oncological subspecialties was communicated orally by the relevant principal investigator, for his defence and discussion to the Oncology community present.

HM hospitals

HM hospitals consists of companies that manage different private medical hospitals, including HM University Madrid, HM University Montepríncipe, HM University Torrelodones, HM University Sanchinarro, HM new Bethlehem and the Center comprehensive Oncology Clara Campal (CIOCC); all of them of great technical and human skills.

Based on a Decalogue and the Hippocratic oath directed by physicians and with the aim of offering a quality medicine, the different centers of HM hospitals have provided with advanced technology and more humane and better qualified staff.

Todos los centros de HM Hospitales funcionan de forma integrada. To do this, there is a corporate structure with centralized services, as well as different management tools. This allows a complementary and synergistic action of structures, services and facilities, with the maximum utilization of the technological and human resources.